Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Audio By Carbonatix

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Apr 30, 2025--

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.

Details of the event are as follows:
Date: Wednesday, May 7, 2025
Time: 1:30 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250430982018/en/

CONTACT: Adicet Bio, Inc.Investor and Media ContactsInvestors:

Anne Bowdidge

[email protected] Belnap

Precision AQ

[email protected]:

Kerry Beth Daly

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH GENETICS CLINICAL TRIALS

SOURCE: Adicet Bio, Inc.

Copyright Business Wire 2025.

PUB: 04/30/2025 07:00 AM/DISC: 04/30/2025 06:59 AM

http://www.businesswire.com/news/home/20250430982018/en